Posted by Michael Wonder on 19 Dec 2022
PHARMAC funds more treatments for people with inflammatory bowel disease
20 December 2022 - Pharmac has today announced funding of ustekinumab (Stelara) for people with inflammatory bowel disease (IBD) and the widening of funded access to infliximab (Remicade) for people with IBD associated arthritis from 1 February 2023.
“We are pleased to announce that ustekinumab will be funded to provide benefits in the response and remission of IBD for people who meet certain eligibility criteria,” says Pharmac’s director of operations Lisa Williams. “We estimate that approximately 500 people with IBD will benefit from use of the medicine in the first year increasing up to a total of 1500 people after a few years.”
